Table 3

The effect of β-blockade on change in lung function, dynamic hyperinflation and peak exercise according to whether the individual had chronic obstructive pulmonary disease

Change; non-COPD (n=23)Change; COPD (n=15)p Value
FEV1 (L)−0.09 (0.32)−0.11 (0.18)0.76
FEV1 (% predicted)−1.9 (5.9)−4.2 (6.5)0.24
FVC (L)0.01 (0.35)−0.09 (0.29)0.30
FVC (% predicted)0.2 (5.7)−2.2 (8.3)0.32
FEV1/FVC−0.01 (0.06)−0.02 (0.06)0.49
RV/TLC (% predicted)−2.1 (3.5)0.5 (5.1)0.27
Raw (kPa/s/L)−0.15 (0.66)−0.13 (0.84)0.90
sGaw (kPa/s)0.01 (0.05)0 (0.01)0.78
sRaw (kPa/s)0.74 (1.89)1.17 (1.87)0.5
IC (L) at rest0 (1.10)−0.05 (0.62)0.46
VO2 at LT (mL/min)−0.21 (1.34)−0.54 (1.40)0.54
VO2 at peak (mL/min)0.11 (2.31)0.21 (2.11)0.90
Oxygen pulse (mL/beat)−1.52 (2.23)−2.17 (2.09)0.42
VE/VO20.97 (3.90)0.48 (3.63)0.70
VE/VCO21.27 (2.33)0.23 (1.72)0.45
Workload (W)−1.1 (7.7)4.3 (9.5)0.08
Heart rate (bpm)−17 (11)−17 (7)0.60
Change in IC (L)—dynamic hyperinflation0.02 (0.24)−0.07 (0.30)0.09
  • FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; LT, lactate threshold; Raw, airway resistance; RV, residual volume; sGaw, specific airway conductance; sRaw, specific airway resistance; TLC, total lung capacity; VCO2, maximal carbon dioxide output; VE, minute ventilation; VO2, maximal oxygen uptake.